Free shipping on all orders over $ 500

MLN2238

Cat. No. M2285
MLN2238 Structure
Synonym:

Ixazomib

Size Price Availability Quantity
5mg USD 95  USD95 In stock
10mg USD 140  USD140 In stock
25mg USD 285  USD285 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

MLN2238 is a potent reversible and specific β5 site of the 20S proteasome inhibitor with an IC50 value of 3.4 nM. Proteasome activity was significantly inhibited in both blood and tumor following a single dose of MLN2238 administered IV at 14 mg/kg or SC at 4 mg/kg. It is active in preclinical models of lymphoma, and that MLN2238 has antitumor activity in a model of lymphoma that is refractory to bortezomib treatment.

Customer Product Validations & Biological Datas
Source Cell Death Dis (2018). Figure 5. MLN2238
Method MTS assay
Cell Lines HepG2 a, Hep3B b, and SNU475 c cells
Concentrations 0-1000 nM
Incubation Time 24, 48, and 72 h
Results Fig. 1d shows that after 48 h MLN2238 significantly inhibited HCC cell proliferation according to the drug concentration.
Chemical Information
Molecular Weight 361.03
Formula C14H19BCl2N2O4
CAS Number 1072833-77-2
Solubility (25°C) DMSO 52 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] No authors listed. Ixazomib

[2] Giuseppa Augello, et al. Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells

[3] Xinghua Wei, et al. MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostate cancer cells by induction of NOXA

[4] Aneel Paulus, et al. The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs

[5] Juan J Gu, et al. MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical mod䲧畸

Related Proteasome Products
NIC-0102

NIC-0102 is an orally potent proteasome inhibitor (pIC50=7.55) that specifically inhibits NLRP3 inflammasome activation.NIC-0102 showed potent anti-inflammatory effects in vivo in a DSS-induced ulcerative colitis model. In addition, NIC-0102 inhibited the production of pro-IL-1β.

Ac-WLA-AMC

Ac-WLA-AMC is a specific 20S constitutive proteasome β5 fluorogenic substrate.

Ac-Nle-Pro-Nle-Asp-AMC

Ac-Nle-Pro-Nle-Asp-AMC is a specific substrate for 26S proteasome.

PR-39

PR-39, a natural proline- and arginine-rich antibacterial peptide, is a noncompetitive, reversible and allosteric proteasome inhibitor.

PSI

PSI (Proteasome Inhibitor 1) is a potent proteasome inhibitor.

  Catalog
Abmole Inhibitor Catalog




Keywords: MLN2238, Ixazomib supplier, Proteasome, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.